MedTrace Logo

Black Barley Study - Barley to Support Food and Drink Innovation (RI-B7-3)

NCT06673212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-11-12

No results posted yet for this study

Summary

Sustained postprandial hyperglycaemia is an independent risk factor for cardiovascular complications and death. Intensive glucose control is the predominant factor to prevent the development of chronic complications in Type 2 Diabetes Mellitus (T2DM). The investigators have shown that phytochemical-rich extracts (in this case anthocyanins and their derivatives) can attenuate glucose response and there is also strong evidence for the role of fibre. Here a selected barley line (rich in anthocyanins and (1,3;1,4)-β-glucan) will be compared to a control barley and control wheat in an acute human dietary intervention (with n=15 healthy volunteers) to explore the potential to modulate postprandial glycaemia and insulinaenemia. An additional secondary outcome will include metabolomics analysis of the blood plasma and urine to detect differences in bioactive compounds including phytochemical metabolites. This will help ensure that barley lines being bred for human food can also deliver benefits for health.

Conditions

Interventions

OTHER

Control Wheat Bread

Ingredients: Wheat Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar

OTHER

Berneray Bere barley bread

Ingredients: Berneray Bere Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar

OTHER

Black Barley bread

Ingredients: Black Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar

Sponsors & Collaborators

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Wendy Russell · University of Aberdeen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2023-05-15
Completion
2024-06-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06673212 on ClinicalTrials.gov